Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01747876 | Study of Safety and Efficacy in Patients With Malignant Rhabdoid Tumors (MRT) and Neuroblastoma | terminated | Phase 1 | 32 | Novartis PharmaceuticalsINDUSTRY | 5 | Nov 22, 2019 | clinicaltrials |
| NCT01114555 |
| Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma |
| completed |
| Phase 2 |
| 34 |
| Memorial Sloan Kettering Cancer CenterOTHER |
| 1 |
| Nov 21, 2019 |
| clinicaltrials |
| NCT00651716 | T Cells in Predicting Acute Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | terminated | — | 150 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT01183884 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma | terminated | Phase 2 | 46 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 14, 2019 | clinicaltrials |
| NCT02177773 | GA-68 DOTA-TOC of Somatostatin Positive Malignancies(DOTA-TOC) | terminated | Phase 1 / Phase 2 | 300 | University of California, San FranciscoOTHER | 1 | Nov 12, 2019 | clinicaltrials |
| NCT01492673 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 29, 2019 | clinicaltrials |
| NCT01334515 | Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | completed | Phase 2 | 52 | Children's Oncology GroupNETWORK | 2 | Oct 21, 2019 | clinicaltrials |
| NCT01183416 | High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01418495 | Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma | completed | — | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01183429 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01183897 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02693171 | Post-Marketing Assessment of Immunogenicity and Safety of Unituxin® in High-Risk Neuroblastoma Patients | terminated | — | 13 | United TherapeuticsINDUSTRY | 1 | Aug 5, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT00539500 | Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma | terminated | Phase 2 / Phase 3 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 26, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00436852 | ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 2 | 92 | Children's Oncology GroupNETWORK | 2 | Jul 17, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00126412 | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | completed | Phase 3 | 251 | GE HealthcareINDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT01313936 | High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma | completed | Phase 1 | 32 | University of California, San FranciscoOTHER | 1 | Apr 29, 2019 | clinicaltrials |
| NCT01802138 | A Pilot Study of Activated T Cell Therapy for Refractory/Relapsed Neuroblastoma | completed | N/A | 6 | Seoul National University HospitalOTHER | 1 | Apr 9, 2019 | clinicaltrials |
| NCT00801931 | Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders | terminated | Phase 1 / Phase 2 | 1 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT02557854 | HIFU Hyperthermia With Liposomal Doxorubicin (DOXIL) for Relapsed or Refractory Pediatric and Young Adult Solid Tumors | withdrawn | Phase 1 | 0 | Theodore LaetschOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT02173093 | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | unknown | Phase 1 / Phase 2 | 40 | University of VirginiaOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00877110 | Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | completed | Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 10, 2019 | clinicaltrials |
| NCT01119560 | Genetic Susceptibility Biomarkers in Children With Neuroblastoma (Also Known as Neuroblastoma Epidemiology in North America [NENA]) | completed | — | 576 | Children's Oncology GroupNETWORK | 2 | Jan 8, 2019 | clinicaltrials |
| NCT01576692 | Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma | completed | Phase 1 | 34 | St. Jude Children's Research HospitalOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT02933333 | G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor | unknown | Phase 4 | 405 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT00793845 | Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma | completed | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01807468 | Haploidentical Stem Cell Transplantation and NK Cell Therapy in Patients With High-risk Solid Tumors | unknown | Phase 2 | 12 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT00754286 | A Randomized Trial of The Effectiveness of Aromatherapy on Chemotherapy Induced Nausea and Vomiting in Children With Cancer | completed | N/A | 132 | Albert Einstein College of MedicineOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT00960063 | A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006) | terminated | Phase 1 | 4 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT01295762 | Immunomonitoring of Children With Neuroblastoma(Immuneuro) | unknown | N/A | 35 | Centre Leon BerardOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT02337309 | SF1126 for Patients With Relapsed or Refractory Neuroblastoma | terminated | Phase 1 | 4 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT00436696 | Genetic Analysis Using Blood or Bone Marrow From Participants With Neuroblastoma or Noncancerous Conditions | completed | — | 9,350 | Children's Oncology GroupNETWORK | 1 | Aug 7, 2018 | clinicaltrials |
| NCT02011126 | Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors | withdrawn | Phase 2 | 0 | Children's Oncology GroupNETWORK | 0 | Aug 7, 2018 | clinicaltrials |
| NCT01462396 | Allogeneic Stem Cell Transplantation for Advanced Neuroblastoma Using MHC Mismatched Related Donors(STALLO) | completed | Phase 1 | 4 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT00923351 | Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma | completed | Phase 1 / Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2018 | clinicaltrials |
| NCT03242603 | Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells(NKEXPGD2) | unknown | Phase 1 / Phase 2 | 5 | National University Hospital, SingaporeOTHER | 1 | Mar 30, 2018 | clinicaltrials |
| NCT00931931 | HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors | completed | Phase 1 | 18 | Timothy CripeOTHER | 1 | Mar 21, 2018 | clinicaltrials |
| NCT00602446 | Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant | terminated | Phase 2 | 4 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT02130869 | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | completed | Phase 1 | 8 | St. Jude Children's Research HospitalOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT02164097 | ODSH + ICE Chemotherapy in Pediatric Solid Tumors | terminated | Phase 1 | 4 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT00003926 | Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | terminated | Phase 1 | 13 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT00944580 | A Vaccine Study for High Risk Cancers | withdrawn | Phase 1 | 0 | Penn State UniversityOTHER | 0 | Nov 24, 2017 | clinicaltrials |
| NCT00405327 | A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation | completed | Phase 2 | 16 | University of Michigan Rogel Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00659984 | N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma | completed | Phase 2 | 15 | Molecular Insight Pharmaceuticals, Inc.INDUSTRY | 1 | Oct 4, 2017 | clinicaltrials |
| NCT00309907 | Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant | completed | Phase 2 | 39 | Children's Oncology GroupNETWORK | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00003513 | Antineoplaston Therapy in Treating Patients With Metastatic, Recurrent, or Refractory Neuroblastoma | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT02745756 | A Combined Cell Therapy Approach to the Treatment of Neuroblastoma | withdrawn | Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 0 | Aug 30, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 17, 2019source: clinicaltrials